Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials

Clinical Therapeutics

Volumn 22, Issue 2, 2000, Pages 209-221

  Grandjean, Etienne ^a   Berthet, Philippe ^b   Ruffmann, Ralf ^c   Leuenberger, Philippe ^d  

^a Phidalsa Institute for Clinical I   (Switzerland)

^b Biometrix SA   (Switzerland)

^c Inpharzam/Zambon Group   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Chronic bronchitis; Chronic obstructive pulmonary disease; Meta analysis; N acetylcysteine; Prevention

Indexed keywords

ACETYLCYSTEINE;

ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEALTH CARE COST; HUMAN; LUNG DISEASE; META ANALYSIS; MORBIDITY; TREATMENT OUTCOME;

EID: 0034023927     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88479-9     Document Type: Article

References (42)

1. 1. Medical Research Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet. 1965;1:775-781.
2. 2. Medical Section of the American Lung Association. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987;136:225-244.
3. 3. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). A consensus statement of the European Respiratory Society (ERS). Eur Respir J. 1995;8:1398-1420.
4. 4. Niederman MS, McCombs JS, Unger AN, et al. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther. 1999;21:576-591.
5. 5. Task Group on Mucoactive Drugs. Recommendations for guidelines on clinical trials of mucoactive drugs in chronic bronchitis and chronic obstructive pulmonary disease. Chest. 1994;106:1532-1537.
6. 6. Kobayashi K, Wanner A. Mucociliary clearance and ciliary activity. In: Chung KF, Barnes PJ, eds. Pharmacology of the Respiratory Tract-Experimental and Clinical Research. New York: Marcel Dekker; 1993:645. Lung Biology in Healthand Disease; vol 67.
7. 6. Kobayashi K, Wanner A. Mucociliaryclearance and ciliary activity. In: ChungKF, Barnes PJ, eds. Pharmacology of theRespiratory Tract-Experimental andClinical Research. New York: MarcelDekker; 1993:645. Lung Biology in Health and Disease; vol 67.
8. 7. Sheffner AL, Medler EM, Jacobs LW, Sarette HP. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. Am Rev Respir Dis. 1964;90:721-729.
9. 8. Ruffmann R, Wendel A. GSH rescue by W-acetylcysteine. Klin Wochenschr. 1991; 69:857-862.
10. 9. Repine JE, Bast A, Lankhorst I, and the Oxidative Stress Study Group. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;156:341-357.
11. 10. Barnes PJ. New therapies for chronic obstructive pulmonary disease. Thorax. 1998;53:137-147.
12. 11. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152 (Suppl):S77-S120.
13. 12. Machin D, Campbell M, Fayers P, Pinol A. Comparing independent groups for binary ordered categorical and continuous data. In: Sample Size Tables for Clinical Studies. 2nd ed. Oxford: Blackwell Scientific; 1997:18-68.
14. 13. Cohen J. Statistical Power Analysis in Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum; 1988.
15. 14. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations - a meta-analysis. JAMA. 1995;273:957-960.
16. 15. Lacasse Y, Wong E, Guyatt GH, et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet. 1996;348:1115-1119.
17. 16. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis. Methods for quantitative synthesis in medicine. New York: Oxford University Press; 1994. Monographs in Epidemiology and Biostatistics; vol 24.
18. 17. Grassi C, Morandini GC. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol. 1976;9:393-396.
19. 18. Lemy-Debois N, Frigerio G, Lualdi P. Oral acetylcysteine in bronchopulmonary disease. Comparative clinical trial with bromhexine. Acta Ther. 1978;3:125-132.
20. 19. Verstraeten JM. Mucolytic treatment in chronic airways obstruction. Double-blind clinical trial with acetylcysteine, bromhexine and placebo. Acta Tuberc Pneumol Belg. 1979;70:71-80.
21. 20. Aylward M, Maddock J, Dewland P. Clinical evaluation of acetylcysteine in the treatment of patients with chronic obstructive bronchitis: A balanced double-blind trial with placebo control. Eur J Respir Dis. 1980;61(Suppl 111):81-89.
22. 21. Brocard H, Charpin J, Germouty J. Etude multicentrique en double aveugle avec acetylcysteine orale vs. placebo. Eur J Respir Dis. 1980;61(Suppl 111):65-69.
23. 22. Gepts L. Oral acetylcysteine treatment in exacerbation of chronic bronchitis in 49 patients. Eur J Respir Dis. 1980;61(Suppl 111): 109. Abstract.
24. 23. Grassi C, and the Multicenter Study Group. Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study. Eur J Respir Dis. 1980; 61(SuppI 111):93-108.
25. 24. Maesen F, Brombacher P. Die Behandlung der chronischen Bronchitis mit oralen Dosen von Acetylcystein. Eine Doppelblindstudie. Therapiewoche Schweiz. 1980; 30:2024-2027.
26. 25. Ravez P, Delwarte J, Libert P, et al. Short treatment of respiratory disorders with an oral mucolytic agent. Double-blind study with acetylcysteine vs. placebo. Eur J Respir Dis. 1980;61(Suppl 111):76. Abstract.
27. 26. Boman G, Bäcker U, Larsson S, et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: Report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis. 1983;64:405-415.
28. 27. Jackson M, Barnes J, Cooksey P. Efficacy and tolerability of oral acetylcysteine (Fabrol®) in chronic bronchitis: A double-blind placebo-controlled study. J Int Med Res. 1984;12:198-205.
29. 28. McGavin CR, and the British Thoracic Society Research Committee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax. 1985; 40:832-835.
30. 29. Meister R. Langzeittherapie mit Acetylcystein Retard-Tabletten bei Patienten mit chronischer Bronchitis. Eine doppel-blinde-placebokontrollierte Studie. Forum Prakt Allg Arzt. 1986;25:18-22.
31. 30. Parr GD, Huitson A. Oral Fabrol (oral N-acetylcysteine) in chronic bronchitis. Br J Dis Chest. 1987;81:341-348.
32. 31. Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetyl-cysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J. 1988;1:351-355.
33. 32. Hansen NCG, Skriver A, Brorsen-Riis L, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med. 1994;88:531-535.
34. 33. Sacks HS, Berrier J, Reitman D, et al. Meta-analyses of randomized controlled trials. N Engl J Med. 1987;316:450-455.
35. 34. Cook DJ, Sackett DL, Spitzer WO. Methodologic guidelines for systematic review of randomized control trials in health care from the Potsdam consultation on meta-analysis. J Clin Epidemiol. 1995;48:161-171.
36. 35. Moher D, Olkin I. Meta-analysis of randomized controlled trials. A concern for standards. JAMA. 1995;274:1962-1964.
37. 36. Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet. 1991;20:123-134.
38. 37. Cotgreave IA. N-Acetylcysteine: Pharmacological considerations and experimental and clinical applications. Adv Pharmacol. 1997;38:205-227.
39. 38. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J. 1997;10:1535-1541.
40. 39. Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis - adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med. 1997;156:1897-1901.
41. 40. Richardson P. Oral N-acetylcysteine: How does it act? Eur J Respir Dis. 1987;70: 71-72.
42. 41. Riise GC, Larsson S, Larsson P, et al. The intrabronchial microbial flora in chronic bronchitis patients: A target for N-acetylcysteine therapy? Eur Respir J. 1994;7: 94-101.